Lennart Kühl

6PUBLICATIONS
22CO-AUTHORS
Molecular targetsBiomaterialsMedical devicesCancer therapy (excl. chemotherapy and radiation therapy)Biologically active molecules
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (6)

|May 19, 2026
Novel bispecific T-cell engagers overcoming acquired EGFR resistance.

|Mar 02, 2023
eIg-based bispecific T-cell engagers targeting EGFR: Format matters.

Lennart Kühl, Annelie K Schäfer, Sebastian Kraft

|Apr 15, 2022
The eIg technology to generate Ig-like bispecific antibodies.

Lennart Kühl, Nadine Aschmoneit, Roland E Kontermann

|Mar 05, 2022
Triple Targeting of HER Receptors Overcomes Heregulin-mediated Resistance to EGFR Blockade in Colorectal Cancer.

Alexander Rau, Nicole Janssen, Lennart Kühl

|Jan 27, 2022
Fc-based Duokines: dual-acting costimulatory molecules comprising TNFSF ligands in the single-chain format fused to a heterodimerizing Fc (scDk-Fc).

Nadine Aschmoneit, Katharina Kocher, Martin Siegemund

|Mar 23, 2021
A bivalent, bispecific Dab-Fc antibody molecule for dual targeting of HER2 and HER3.

Alexander Rau, Katharina Kocher, Mirjam Rommel

Pageof 1

Frequent Collaborators

5 joint publications

Roland E Kontermann

5 joint publications

Oliver Seifert

4 joint publications

Nadine Aschmoneit

3 joint publications

Monilola A Olayioye